Medivasa, s.r.o.

Žilina 1001

0 studies enrolling now · 13 studies all time

What they study most

Acute Coronary Syndrome, Atrial Fibrillation, Cardiovascular Disease, Coronary Artery Disease, Diabetes Mellitus, Type 2, Diabetes, Type 2, Dyslipidemia, Heart Failure, Myocardial Infarction, Obesity, Obesity and Overweight, Overweight

Studies at this site

• A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) — Running, not enrolling
• Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity — Running, not enrolling
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% — Completed
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early
• A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin — Completed
• Dose-response Relationship Study of S42909 on Leg Ulcer Healing — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin — Completed
• Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects — Completed
• Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) — Stopped early